Adulteration of natural flavonoids with cheap synthetic coal-tar-derived aglycones is a severe regulatory risk for premium brands. Xi'an Tihealth guarantees 100% natural extraction exclusively from mature Sophora japonica L. fruits. We establish full batch-to-batch traceability from raw biomass to crystallites and verify origin authenticity via HPLC phytochemical fingerprinting and stable carbon isotope ratio analysis (δ13C), ensuring fully compliant documentation for high-end audit portfolios.

Unhydrolyzed glycosides significantly increase the molecular size of the material, diluting active purity and skewing absorption kinetics in dietary formulations. Our production system utilizes a highly calibrated acidic cleavage process that ensures a **free aglycone ratio of ≥99.0%**. High-Performance Liquid Chromatography (HPLC) is employed to verify that residual, heavy sugar-linked glycoside peaks are practically non-detectable, ensuring pure, uncompromised bioavailability.

Due to its hydrophobic aglycone molecular structure, pure Kaempferol exhibits poor aqueous solubility, causing immediate sedimentation. For brands developing RTD wellness liquids, cosmetic serums, or effervescent tablets, our R&D team can deliver customized **liposomal encapsulation** or **cyclodextrin-complexed water-soluble Kaempferol** specs, which exponentially increase dispersion stability and aqueous kinetics without compromising molecule potency.

To comply with the ultra-strict safety rules of the United States Pharmacopeia (USP <467>) and the European Pharmacopoeia (EP 5.4), we do not use toxic chlorinated hydrocarbons or aromatic solvents. Our purification system operates strictly using eco-certified Supercritical CO₂ fluid polishing and food-grade ethanol as the sole crystallization phase. Decompression vacuum drying guarantees that residual ethanol is consistently kept **under 10 ppm (0.001%)**, which is virtually non-detectable.

Static charge buildup is a common manufacturing challenge that causes crystalline powders to adhere to machine hoppers and nozzles, resulting in uneven dosing weights. Tihealth addresses this by integrating a specialized crystal habit modification phase during low-temperature precipitation, which stabilizes the polymorph state. Combined with precision micro-milling and anti-static screening to achieve a uniform 80-mesh size and balanced bulk density (0.35-0.55 g/ml), our powder ensures excellent flowability on automated solid-dose production lines.